HomeSmall Caps
Share

Small caps last week: Russell 2000 outpacing S&P 500 YTD, Sellas cancer vaccine trial

Lyudmila Milevskaya

Lyudmila Milevskaya

Lucky Strike advanced after founder Thomas Shannon proposed taking the company private / Photo: www.luckystrikeent.com

Lucky Strike advanced after founder Thomas Shannon proposed taking the company private / Photo: www.luckystrikeent.com

Last week, Sellas Life Sciences said its experimental vaccine for acute myeloid leukemia met the primary endpoint of its phase III trial. Meanwhile, bowling alley operator Lucky Strike’s founder offered to buy out shareholders and take the company private, while protein shake maker BellRing Brands issued an upbeat guidance for next year. Oninvest also looked at how the smid-cap-tracking Russell 2000 has outpaced the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average year to date. These were the top stories in small caps for the week of November 16-20.

Small caps outpacing the S&P 500 YTD

At Thursday’s close, the Russell 2000 had gained 7% year to date, outpacing the S&P 500, up 4.8%, the Nasdaq Composite, up 2.7%, and the Dow Jones Industrial Average, up 2.2%. Barron’s sees small caps, particularly value stocks, as a way to diversify portfolios. The iShares Russell 2000 Value ETF gained 15.5% versus 5.5% for its growth counterpart. Georgy Timoshin, a senior analyst at Freedom Finance Global, cautions that high interest rates remain a risk for small-cap companies and that outperformance by defensive stocks alone does not warrant a larger allocation. 

Spin Master’s management is counting on the holiday season to get revenue growing again / Photo: Facebook / Spin Master

Toymaker Spin Master bets on PAW Patrol and holiday sales to revive growth

Sellas vaccine extends survival in leukemia patients

Shares of biotech Sellas Life Sciences surged 156% on Tuesday after the release of trial results for its blood cancer vaccine. Sellas tested galinpepimut-S in patients with acute myeloid leukemia who had entered their second or a later remission after treatment and were ineligible for a donor stem cell transplant. Topline results from the phase III trial showed the vaccine reduced the risk of death by 41%. Median overall survival was 24 months with the vaccine versus 14.7 months with the best available treatment.

Sellas plans to discuss the path to approval and the possibility of an accelerated filing with the U.S. Food and Drug Administration. The company plans to hold the meeting and continue preparing its application in the first half of next year.

The equal weight index slipped after rising 26.5% in the first half of the year / Photo: Shutterstock.com

An Oninvest index of AI small caps lost 3% in 3Q26. Three stocks bucked the trend.

Lucky Strike founder offers to take company private

Shares of Lucky Strike Entertainment, which operates bowling alleys and water parks, jumped around 26% on Tuesday to $4.17 apiece. The day before, the company said its founder and CEO, Thomas Shannon, had offered $4.35 per share for the Class A shares he and his affiliates do not already own. The offer represents a 31% premium to Monday’s close.

The board plans to form a special committee to review the proposal. Under its terms, holders of a majority of the Class A shares that Shannon and his affiliates do not own must also approve the deal. If the deal goes through, Lucky Strike will go private and delist while continuing to operate. The offer is preliminary and could be withdrawn.

It came as Lucky Strike grappled with weak same-store sales and a widening loss. Revenue in the fiscal first quarter, ended September 27, rose 3.5% year over year to $302.6 million, while same-store sales fell 2.6%. The net loss widened to $25.7 million from $13.8 million a year earlier. The company cited lower consumer spending as one factor weighing on parts of the business.

Ubisoft shares are down 45% year to date / Photo: LongJon / Shutterstock.com

Assassin's Creed maker Ubisoft sees holiday bookings down 26% amid GTA VI launch

BellRing Brands jumps on fiscal 4Q sales beat, 2027 guidance

Shares of protein shake maker BellRing Brands rose 24.07% on Wednesday after the company reported results and issued guidance for the new fiscal year. Fourth-quarter revenue rose 6.8% year over year to $692 million versus around $658 million expected by analysts. A 14.9% increase in sales volume offset an 8.1% decline in pricing and product mix combined.

For fiscal 2027, ending September 2027, the management expects adjusted EBITDA of $310-350 million, up 7-21% from $288.8 million the previous year. BellRing also plans to generate at least $100 million in gross savings over three years by streamlining its supply chain. The management sees room to grow by selling more shakes in convenience stores and introducing new products, including a sparkling protein drink.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News